Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis
- PMID: 12942698
Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis
Abstract
Objective: To evaluate serum matrix metalloproteinase 3 (MMP-3) levels in comparison to C-reactive protein (CRP) in periods with and without progression of radiological damage in patients with early rheumatoid arthritis (RA).
Methods: Thirty-two patients with RA and radiological progression (> or = 5 points according to the Sharp/van der Heijde method) during 6 months followed by a 6-month period without radiological progression (< or = 1 point) were selected from a prospective follow-up study of early RA patients. Serum MMP-3 levels, CRP, the erythrocyte sedimentation rate (ESR), disease activity index (DAS), swollen joint count (SJC), tender joint count (TJC), and Ritchie articular index (RAI) were measured monthly and results were transformed into mean values for the 6-month periods.
Results: During the period with radiological progression the mean serum MMP-3 correlated significantly with the mean CRP (r = 0.68, p < 0.001), ESR (r = 0.54, p = 0.001) and swollen joint count (r = 0.48, p = 0.006). In the period without radiological progression the mean serum MMP-3 only correlated with the mean CRP (r = 0.44, p = 0.012). Individual changes--expressed in percentages (%)--between the two periods showed a decrease in both the mean serum MMP-3 and CRP in 19 and an increase in 3 patients, in parallel with other markers of disease activity in these patients (69% of cases). The individual change (%) in mean serum MMP-3 or CRP did not correlate with the difference in radiological progression between the two periods.
Conclusions: Serum MMP-3 and CRP are closely related and there seems to be no difference between serum MMP-3 and CRP with regard to the monitoring of the progression of radiological damage.
Similar articles
-
Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression.J Rheumatol. 2000 Dec;27(12):2761-8. J Rheumatol. 2000. PMID: 11128661
-
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.J Rheumatol. 2002 May;29(5):883-9. J Rheumatol. 2002. PMID: 12022344 Clinical Trial.
-
Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study.Arthritis Res Ther. 2015 Oct 14;17:289. doi: 10.1186/s13075-015-0803-2. Arthritis Res Ther. 2015. PMID: 26467222 Free PMC article.
-
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.Rheumatol Int. 2007 Jul;27(9):793-806. doi: 10.1007/s00296-007-0357-y. Epub 2007 May 16. Rheumatol Int. 2007. PMID: 17505829 Review.
-
MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis.Best Pract Res Clin Rheumatol. 2018 Aug;32(4):550-562. doi: 10.1016/j.berh.2019.01.006. Epub 2019 Feb 14. Best Pract Res Clin Rheumatol. 2018. PMID: 31174824 Review.
Cited by
-
TRPV4 as a therapeutic target for joint diseases.Naunyn Schmiedebergs Arch Pharmacol. 2015 Apr;388(4):437-50. doi: 10.1007/s00210-014-1078-x. Epub 2014 Dec 18. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25519495 Free PMC article. Review.
-
Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.Rheumatol Int. 2007 Jun;27(8):715-22. doi: 10.1007/s00296-007-0338-1. Epub 2007 Apr 11. Rheumatol Int. 2007. PMID: 17426976
-
Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis.Arthritis Res Ther. 2004;6(3):R199-207. doi: 10.1186/ar1164. Epub 2004 Mar 8. Arthritis Res Ther. 2004. PMID: 15142265 Free PMC article.
-
Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity?Clin Rheumatol. 2009 Oct;28(10):1127-34. doi: 10.1007/s10067-009-1223-y. Epub 2009 Jul 14. Clin Rheumatol. 2009. PMID: 19597699 Review.
-
Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.BMC Musculoskelet Disord. 2008 May 28;9:74. doi: 10.1186/1471-2474-9-74. BMC Musculoskelet Disord. 2008. PMID: 18507823 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous